drugset / Trial / NCT01482936

Pharmacokinetic (PK) Study of OxyNorm Injections in Chinese Patient

NCT01482936

Phase 1 Completed 44 enrolled Mundipharma (China) Pharmaceutical Co. Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a single center, open label, randomized, parallel group single dose intravenous (i.v.) administration study. The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.

Timeline

Start
2010-05
Primary completion
2011-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxycodone Other / unclassified 2.5 mg Intravenous
Subject Oxycodone Other / unclassified 5 mg Intravenous
Subject Oxycodone Other / unclassified 10 mg Intravenous

Indications

No indication recorded.